Nuclear S6K1 regulates cyclic AMP response element-dependent gene transcription through the activation of the mTOR signaling pathway - Evidence review
The study shows that, in cervical cancer cells, S6K1 activated by growth signals can enter the nucleus and associate with gene transcription mechanisms. Independent research confirms nuclear functions of the mTORC1-S6K axis, but does not directly replicate the CREB/c-JUN interaction. The evidence remains primarily mechanistic, not clinical, and dependent on the specific cellular model.
- Published 17/11/2026
- Updated 17/11/2026
- Article history
ABSTRACT
The analyzed study examined whether S6K1, a protein activated downstream of the mTORC1 complex, also performs functions within the cell nucleus in addition to its well-known role in protein synthesis. In cervical cancer cells, the authors observed that the phosphorylation of S6K1 at the Thr389 position, promoted by the presence of serum, was associated with its nuclear localization. Under these conditions, S6K1 interacted with CREB, a factor that contributes to activating specific genes, and increased the activity of a promoter regulated by CRE elements. Experimental reduction of S6K1 decreased the expression of c-JUN, a gene involved in the proliferative response.
In paragraph 4.7, “mTORC1 - S6K1”, “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi uses this research to support a specific point: after activation, S6K1 can reach the nucleus and participate in the regulation of gene expression. Independent studies confirm that mTORC1 can be active in the nucleus and that S6 kinase activity contributes to transcriptional programs linked to growth. However, there is no direct independent replication of the S6K1-CREB interaction and the regulation of c-JUN described in the analyzed study. Furthermore, a study on HeLa cells did not detect nuclear S6K1 using their specific methods. The most prudent conclusion is therefore that the narrative is supported primarily at a mechanistic and cellular level.
Analyzed study
Nuclear S6K1 regulates cAMP-responsive element-dependent gene transcription through activation of mTOR signal pathway
DOI: 10.1016/j.bbrc.2022.01.015
PMID: 35078109
The research question was whether S6K1, a kinase (an enzyme that modifies other proteins by adding phosphate groups) known primarily for acting in the cytoplasm, can enter the nucleus and contribute directly to gene control. The hypothesis was that the activation of the mTOR pathway, which is important for translating the availability of nutrients and growth factors into cell growth signals, does not only produce effects on protein synthesis but also on gene transcription.
This question is relevant to the passage in the book because the paragraph does not attribute the entire genetic regulation of the cell to S6K1. Instead, it argues that, once phosphorylated, S6K1 can translocate into the nucleus and participate in the regulation of gene expression. The study analyzed addresses precisely this segment of the chain: mTORC1 activation, S6K1 phosphorylation, nuclear distribution, and association with elements that regulate transcription.
As this is experimental research conducted on tumor cell lines, it can document molecular phenomena in the studied model. However, it cannot establish that the same mechanism occurs with identical intensity in healthy tissues, in all tumors, or in the human body.
Materials and methods of the original study
The available material is only the abstract of the publication. The study used human cervical cancer cells and HeLa cells, a cell line derived from cervical carcinoma. The authors compared conditions with serum, which provides growth factors to the cells, and serum-deprivation conditions. They also used rapamycin, a drug that selectively inhibits a portion of mTORC1 signaling.
The main variables reported in the abstract were the phosphorylation of S6K1 at Thr389, its distribution between the cytoplasm and the nucleus, its interaction with CREB, and the activity of a CRE promoter via a luciferase assay. This test uses a light signal to estimate how active a promoter is. The level of S6K1 was also experimentally reduced via knockdown to evaluate the effect on c-JUN expression. In HeLa cells, 891 promoter regions to which S6K1 bound directly were identified.
The number of independent biological experiments, the selection criteria for the cell lines, the concentrations and duration of the treatments, the details of the cell fractionation techniques, the statistical tests, the significance values, and the quantitative measurements are not reported in the available material.
Results
The main result indicates that S6K1 was not statically confined to the cytoplasm. In cervical tumor cells, its presence in the nucleus was serum-dependent. When serum was removed or cells were treated with rapamycin, S6K1 phosphorylation at Thr389 decreased, and S6K1 was retained in the cytoplasm. In simple terms, growth signals and the mTOR pathway were associated with both the activation of S6K1 and its ability to reach the nucleus.
The authors also detected an interaction between endogenous S6K1, i.e., produced naturally by the cells, and CREB. S6K1 increased the activity of a promoter containing CRE elements, which are short DNA sequences recognized by CREB. When S6K1 was reduced via knockdown, c-JUN expression decreased. The direction of the effect is therefore clear: less S6K1 in the cells corresponded to lower c-JUN expression in the experimental model.
The study also reported that the binding of CREB and S6K1 to the c-JUN promoter changed after serum restimulation and was associated with active epigenetic markers. Epigenetics includes modifications that influence gene accessibility without changing the DNA sequence. Finally, 891 promoter regions directly bound by S6K1 were identified in HeLa cells. The abstract does not provide the complete list of genes, the intensity of the binding, quantitative variations, or P-values.
Interpretation
The biological significance of the results is that S6K1 may expand the function of the mTORC1 signal. Instead of being limited to modifying proteins in the cytoplasm and promoting the production of new proteins, a portion of activated S6K1 could contribute in the nucleus to making certain genes more or less usable by the cell.
The segment documented by the publication subject to the Evidence Review is: growth signals and mTORC1 activity associated with the phosphorylation of S6K1 at Thr389 → increased nuclear localization of S6K1 → association with CREB, CRE promoter activity, and regulation of c-JUN. This is consistent with the statement in the book that S6K1 can participate directly in the regulation of gene expression after being phosphorylated.
However, it is necessary to distinguish between observation and interpretation. The observation concerns the cellular distribution of S6K1, the interaction with CREB, the variation in promoter activity, and the reduction of c-JUN after knockdown. The authors' hypothesis is that S6K1 may act on DNA through epigenetic mechanisms or by recruiting transcription factors. The study does not prove that S6K1 directly regulates all 891 identified promoters, nor does it prove that this nuclear activity is necessary for human physiology or for a specific disease.
Independent confirming evidence
A first confirmation concerns the upstream step of the narrative: the existence of mTORC1 activity in the nucleus. Zhou and colleagues studied NIH3T3 cells, murine fibroblasts frequently used in cell signaling models, with fluorescent biosensors localized in the nucleus and with a form of S6K1 experimentally retained in the nucleus. Stimulation with PDGF, a growth factor, increased the phosphorylation of nuclear S6K1 by 34 ± 4 fold; rapamycin and Torin1 inhibited this response. The authors also observed a nuclear response to insulin signals in 3T3L1 adipose cells. The work does not demonstrate the spontaneous translocation of S6K1 or its interaction with CREB, but it directly confirms that the nuclear compartment can host mTORC1 signaling capable of phosphorylating S6K1 [1].
A second independent line supports the link between the mTOR-S6K1 axis and transcriptional regulation. Hannan and colleagues studied the transcription of ribosomal genes in murine cells and nuclear extracts. Inhibition of mTOR with rapamycin reduced ribosomal RNA transcription, while active S6K1, but not an inactive form of the enzyme, restored transcriptional activity in extracts from rapamycin-treated cells. The final target examined was UBF, a factor that helps initiate the transcription of genes for ribosomal RNA. The result does not concern CREB or c-JUN, but it confirms that S6K1 can contribute to a transcriptional program regulated by mTOR [2].
A third piece of evidence broadens the picture in a living organism. Chauvin and colleagues compared the livers of normal mice and mice lacking both S6K1 and S6K2 kinases after feeding. The absence of the kinases was associated with a defect in the transcriptional program of ribosome biogenesis, that is, the production of the components necessary to build ribosomes. Over 75% of the factors in this program were found to be controlled by S6Ks. Even mutations that prevented the phosphorylation of the ribosomal protein S6 reduced the activity of these promoters. This evidence does not prove a specific nuclear function of S6K1 in cervical cells, but it is biologically consistent with the idea that the activity of S6 kinases influences the expression of groups of genes linked to growth [3].
Overall, independent research confirms three levels of the narrative: mTORC1 can be active in the nucleus; S6K activity can contribute to transcriptional processes; and the absence of S6K alters genetic programs in vivo. None of them autonomously and completely replicates the S6K1-CREB-c-JUN sequence observed in the analyzed study. For this reason, the confirmation of the book's general formulation is more solid than the confirmation of the specific mechanism proposed by the authors.
Conflicting evidence
Directly relevant evidence suggests caution. Iadevaia and colleagues studied HeLa cells and, while they detected mTORC1 and its component Raptor in the nucleus and nucleolus, they were unable to detect S6K1 in the nucleus or nucleolus using the fractionation and immunoblotting methods employed. The same authors observed that this finding conflicted with previous studies reporting nuclear S6K1 after phosphorylation at Thr389, proposing different cell lines or nuclear levels too low to be measured as possible explanations [4].
This result does not eliminate the scientific correspondence between the analyzed study and the book paragraph. However, it shows that the nuclear localization of S6K1 is not necessarily identical in all cells, under all growth conditions, or with all experimental methods. The nuclear function of S6K1 therefore appears to be dependent on the biological context and the sensitivity of the techniques used. No directly conflicting evidence sufficiently relevant to the specific S6K1-CREB interaction or the reduction of c-JUN after knockdown has been identified; this does not prove the absence of contrary results.
Summary table of evidence
The table distinguishes the study subject to the Evidence Review from the independent publications used to evaluate the same narrative in the book paragraph.
| Reference | Study type | Population or model | Main result | Direction of evidence | Strength of evidence |
|---|---|---|---|---|---|
| Original study | Cellular and molecular | Human cervical cancer cells and HeLa cells | Serum and mTOR activity associated with phosphorylation, nuclear localization of S6K1, and regulation of CRE promoters. | direct confirmation | moderate |
| [1] | Cellular with biosensors and targeted manipulations | NIH3T3 fibroblasts and 3T3L1 adipocytes | Growth factors and insulin increase nuclear mTORC1 activity; mTORC1 phosphorylates S6K1 localized in the nucleus. | direct confirmation | moderate |
| [2] | Cellular and biochemical | Murine NIH3T3 and FM3A cells, nuclear extracts | mTOR inhibition reduces ribosomal transcription; active S6K1 restores transcriptional activity in rapamycin-treated extracts. | indirect confirmation | moderate |
| [3] | Animal and transcriptomic | Liver of mice with S6K1 and S6K2 deletion | The absence of S6 kinases reduces the transcriptional program of ribosome biogenesis after feeding. | biologically consistent evidence | moderate |
| [4] | Cellular | HeLa cells | mTORC1 is detected in the nucleus and nucleolus, while nuclear S6K1 is not detected with the methods used. | discordant evidence | low |
Confirmation of the evidence
Claim in the book
In section 4.7, “mTORC1 - S6K1”, of the book “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, it is stated that S6K1 is a key effector of mTORC1 and that, once phosphorylated, it can translocate into the nucleus, where it directly participates in the regulation of gene expression.
Growth signals and nutrients → mTORC1 → S6K1 phosphorylation → S6K1 nuclear localization → gene transcription regulation
The publication subject to the Evidence Review was used in the book to support the following passage: after mTOR-dependent activation, S6K1 can reach the nucleus and participate in the regulation of gene expression, expanding the biological effects of the signal transmitted by mTORC1.
The analyzed publication documents, in cervical cancer cells, an experimental link between S6K1 phosphorylation, its presence in the nucleus, and gene regulation activity associated with CREB and c-JUN. This justifies its use in the section "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi: it supports the nuclear and transcriptional segment of S6K1 function, not the entire metabolic cascade attributed to mTORC1.
Independent evidence provides convergent but incomplete confirmation. In murine cells, mTORC1 can be active in the nucleus in response to growth factors and insulin, and can phosphorylate an S6K1 experimentally confined to that compartment [1]. Other experiments indicate that the mTOR-S6K1 axis can support ribosomal gene transcription [2], while studies in mice show that the absence of S6 kinases reduces transcriptional programs linked to ribosome biogenesis [3]. However, the failure to detect nuclear S6K1 in HeLa cells by another group demonstrates that the phenomenon may depend on the cell line or the analytical method [4].
Overall level of confirmation
MECHANISTIC CONFIRMATION
The passage is well-supported by cellular experiments and independent evidence linking mTORC1 and S6K to nuclear and transcriptional processes. However, the demonstration remains primarily molecular and dependent on the experimental model; direct validation in humans and an independent replication specific to the S6K1-CREB-c-JUN sequence are lacking.
Conclusions
The study analyzed directly supports, within its cellular model, the idea that activated S6K1 can localize to the nucleus and associate with gene regulation mechanisms. Independent literature confirms that mTORC1 possesses nuclear activity and that S6 kinases contribute to transcriptional growth programs. However, the specific evidence regarding CREB and c-JUN requires further independent validation. The book's narrative is therefore supported at a mechanistic level, without being automatically extendable to human physiology or disease.
Overall assessment
The nuclear function of S6K1 is moderately supported by convergent cellular experiments and data linking the mTOR-S6K axis to transcription. Consistency with the book's paragraph is good, but the confirmation remains mechanistic: the phenomenon varies between cellular models and has not been demonstrated as a general process in humans.
References
[1] Location-specific inhibition of Akt reveals regulation of mTORC1 activity in the nucleus
[2] mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF†
[3] Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program
[4] mTOR signaling regulates the processing of pre-rRNA in human cells
Editorial note
Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.
The manuscript was also subject to independent peer review prior to publication.
To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.